Company Overview and News

51
What Cigna Investors Should Expect From Its Latest Victory

2018-09-19 investorplace
Cigna (NYSE:CI) was recently granted an early termination of the antitrust waiting period by the U.S. Department of Justice (DOJ) for its proposed acquisition of pharmacy benefit manager Express Scripts (NASDAQ:ESRX). With this, Cigna has managed to cross a major hurdle in the path of this deal. Notably, this transaction had received friction from CI stock investor Carl Icahn, who urged the shareholders of the companies involved to vote against the deal on concerns that it would hardly benefit Cigna, given the headwinds faced by Express Scripts.
AMZN CI CVS AET ESRX

1
ESRX / Express Scripts Holding Co. FORM 8-K (Current Report)

2018-09-18 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
ESRX

49
Top Analyst Upgrades and Downgrades: AMD, Apache, Gold Fields, Marvell, Micron, Oracle, Starbucks, Transocean, United Rentals, Walmart and More

2018-09-18 247wallst - 6
Stocks were indicated to open higher on Tuesday. U.S. equity indexes remain very close to their all-time highs, while most international markets are not close to their highs. One issue that has to be considered is that investors have seen less upside from buying on market pullbacks than in prior years. Investors also need to consider how they want to have their investments positioned for the rest of 2018.
APA GFI.WI AMD WMT ISCA CL BKU MS RIG GFIOF ORCL MRVL FDX AKCA MU URI TRI SBUX GFI ESRX

16
3 Cheap Stocks to Buy Before They Skyrocket

2018-09-17 investorplace
The S&P 500 has risen nearly 10% this year, but its increase over the past few years has had a substantial impact on valuations. Notably, ever since the S&P’s upward rise in 2009, the average price-earnings ratio has increased significantly, from just under 15.5 in 2010 to a high of over 25 today.
SNI DISCB DISCA NFLX DISCK CVS MU MS UNH ESRX DISC

33
Healthcare And Biotechnology Dashboard - Update

2018-09-11 seekingalpha
This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages.
NKTR INCY IBB CVS PKI ESRX

1
ESRX / Express Scripts Holding Co. 8-K (Current Report)

2018-08-29 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
ESRX

1
ESRX / Express Scripts Holding Co. FORM 8-K (Current Report)

2018-08-24 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ESRX

3
Synergy Pharmaceuticals: Troy Hamilton Continues To Deliver

2018-08-24 seekingalpha - 2
Wall Street continues to be on a wait-and-see mode as it continues to wait for the conclusion of strategic review.
SGYP CPHRF SGYPW ESRX

14
CVS Health's Risks Mounting

2018-08-20 seekingalpha - 1
CVS Health continues to face long-term threats to its business, and relatively weak near-term performance expectations have done little to inspire confidence.
WBA CVS ESRX

153
Stocks To Watch: Alibaba, Target And Energy Plays To Center Stage

2018-08-18 seekingalpha - 3
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
FOCS PDD LGCYP LGCYO QEP TJX EL AVGO ABBV FTNT KLXI CORR ESES SDPI TENB LNR RRS WPX FSBW ESTE NPTN ERF BABA SDCJF PAY MSFT GPS MPOYQ HRS FL MLM BLCN MOS SEA CLPS LB CLB ROSEU DBX CF CRDAF KSS CRDAD CI SSI JAG ROSE SNDE DAVA SJM UNT HUM EOG BHI RGRYY MU LGCY SBUX MNK WRD LOW JKS TOL LONE ERF CLB FTK AMAT CRD KEG KEGX SOXX STT FSWB WLL AQST SM LBRT BV LLEX ADIL NBR RGRLF CMG RRC INTU HIMX BJRI EDUC BE MPO ABBV BA ESRX ECR JG NDLS WPXP MTB RRL VMW ALRM LQDA RMBS ECA CANG ICD OPRA IBM WISA CDEV JGPK LYB COG ECA SPDI SBOW PHX TGT NTR BRY HPQ URBN TELL

42
Cigna: Pyrrhic Victory?

2018-08-17 seekingalpha
Despite the previous opposition from Carl Icahn, Cigna shareholders are expected to approve the company’s $67 billion acquisition of Express Scripts on August 24.
AMZN CI ESRX

1
ESRX / Express Scripts Holding Co. 425 (Prospectus)

2018-08-16 sec.gov
425 FILED BY EXPRESS SCRIPTS HOLDING COMPANY PURSUANT TO RULE 425 UNDER THE SECURITIES ACT OF 1933 AND DEEMED FILED PURSUANT TO RULE 14a-12 UNDER THE SECURITIES EXCHANG
ESRX

76
Tracking Glenn Greenberg's Brave Warrior Advisors Portfolio - Q2 2018 Update

2018-08-16 seekingalpha
The largest three positions are Alliance Data Systems, Alphabet, and Charles Schwab, and they add up to ~43% of the portfolio.
CCV LBTY NLSN CCZ GOOG AR BAC LBTYK LILAB HCA CI CMCSK BAM BAMGF BAC CMCSA BBU LBTYB LBTYA SCHW PRI JPM GOOGL CCV.CL LILAK ADS BAMKF ESRX LILA

1
ESRX / Express Scripts Holding Co. 425 (Prospectus)

2018-08-15 sec.gov
425 FILED BY EXPRESS SCRIPTS HOLDING COMPANY PURSUANT TO RULE 425 UNDER THE SECURITIES ACT OF 1933 AND DEEMED FILED PURSUANT TO RULE 14a-12 UNDER THE SECURITIES EXCHANG
ESRX

1
ESRX / Express Scripts Holding Co. FORM 8-K (Prospectus)

2018-08-13 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ESRX

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to ESRX / Express Scripts Holding Co. on message board site Silicon Investor.

Express Scripts(ESRX)-King of PBMu0027s Express Scripts(ESRX)-King of PBMu0027s Express Scripts(ESRX)-King of PBMu0027s What do you think about ESRX? What do you think about ESRX? What do you think about ESRX?
CUSIP: 30219G108